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Abstract
Background: Although a large number of studies have been conducted in relation to ovarian response
and pregnancy after GnRH agonist and GnRH antagonist controlled ovarian hyperstimulation protocols,
most of them used single or combinations of a few predictive factors, and none included the stimulation
protocol in the multivariable analysis. The present study was thus primarily designed to investigate the
predictive value of the stimulation protocol and to analyze the possible relationships between stimulation
protocols and treatment outcomes after adjusting for a large set of variables that potentially affect
reproductive outcomes. Factors related to pregnancy achievement and predictive of the number of
oocytes retrieved and high quality of the embryos obtained were also analyzed.
Methods: To analyze the impact of GnRH ovarian stimulation protocols on the independent predictors
of ovarian response, high quality embryos and clinical pregnancy, two groups out of 278 ICSI treatment
cycles were compared prospectively, 123 with a GnRH agonist and 155 with a GnRH antagonist, with
multivariable analysis assessing outcomes after adjusting for a large set of variables.
Results: Antagonists were significantly associated with lower length and total dose of GnRH, lower length
of rFSH, and higher numbers of oocytes and high quality embryos, whereas the agonist presented a higher
fertilization rate and probability of pregnancy. Significant predictors of retrieved oocytes and high quality
embryos were the antagonist protocol, lower female age, lower serum levels of basal FSH and higher total
number of antral follicles. Significant predictors of clinical pregnancy were the agonist protocol, reduced
number of attempts, increased endometrial thickness and lower female age. The probability of pregnancy
increased until 30 years-old, with a decline after that age and with a sharp decline after 40 years-old.
Conclusion: The models found suggest that not only the protocol but also factors as female age, basal
FSH, antral follicles, number of attempts and endometrial thickness should be analyzed for counselling
patients undergoing an ICSI treatment.
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Background
The most common ovarian stimulation regimens pres-
ently used are those employing gonadotropin-releasing
hormone (GnRH) agonists or antagonists to prevent a
premature LH surge [1]. Although there is controversial
discussion about the better regimen choice [2], clinical
advantages of GnRH antagonists over agonists are the
absence of the initial stimulation gonadotropin release
(flare-up effect) and, as a consequence, a more direct,
immediate and reversible suppression of gonadotropin
secretion by blocking the GnRH receptor, which allows
their use without the need for a desensitization period [3].
Multicenter, randomized, prospective studies also
revealed that exposure to GnRH antagonists is shorter and
that the amount of exogenous gonadotropins needed as
well the occurrence of ovarian hyperstimulation syn-
drome (OHSS) is reduced. Although patients using the
antagonist regimen had lower number of oocytes and
embryos, the percentage of mature oocytes and the fertili-
zation and pregnancy rates were identical in both groups
[1,3-9]. However, meta-analyses have led to discordant
conclusions, showing lower implantation and pregnancy
rates with antagonists [10-13], or no significant differ-
ences between the two protocols regarding prevention of
the premature LH surge and occurrence of OHSS [12], or
the probability of live birth [14]. Some authors thus sug-
gested that the purpose of GnRH analogues can be
reached either by a long agonist protocol or an oral con-
traceptive pretreated fixed antagonist protocol [15].
Several studies have been performed to identify predictors
of ovarian response, such as female age, ovarian volume,
number of antral follicles, ovarian stromal blood flow,
serum FSH, LH, estradiol and inhibin B, cigarette smoking
and body mass index. Similarly, predictors of pregnancy
achievement were studied regarding female age, serum
FSH, estradiol and inhibin B, ovarian volume, endome-
trial thickness, embryo quality, smoking status, body
mass index and parity [16-33].
Although these studies have been conducted in relation to
ovarian response and pregnancy, most of them used sin-
gle or combinations of a few predictive factors, and none
included the stimulation protocol in the multivariable
analysis. The present study was thus primarily designed to
investigate the predictive value of the stimulation proto-
col and to analyze the possible relationships between
stimulation protocols and treatment outcomes after
adjusting for a large set of variables that potentially affect
reproductive outcomes. Factors related to pregnancy
achievement and predictive of the number of oocytes
retrieved and high quality of the embryos obtained were
also analyzed.
Methods
Patients
Under informed consent, a total of 278 women were
included. They were among those undergoing controlled
ovarian hyperstimulation with a GnRH agonist or a GnRH
antagonist protocol for an infertility treatment ICSI cycle.
Women starting an infertility treatment ICSI cycle were
followed forward in time towards the results of treatment.
To use comparable groups of women, data was collected
by physicians with a large experience in reproductive
medicine based on the ovarian stimulation protocols rou-
tinely used in two different years and not based on a clin-
ical judgement made by the physician in accordance with
the patient's response in previous attempts. All data was
obtained by the same team, reducing the variability
related to measurement due to different observers with
different practices. For all women, the number of previous
attempts was considered and for cases that underwent
more than one embryo transfer only the last cycle was
included. Criteria for inclusion were: both ovaries present,
with no morphological abnormalities; normal ovulatory
cycle (25–35 days); basal FSH (day 3) serum level < 10
mIU/mL; no history of poor ovarian response; and a body
mass index of 18–27 kg/m2. All patients and partners had
a normal karyotype.
Controlled ovarian hyperstimulation protocols
For the GnRH agonist long protocol (n = 123), buserelin
acetate (0.6 mg/d, sc; Suprefact: Hoechst, Frankfurt, Ger-
many) was started in the mid-luteal phase of the previous
cycle. After pituitary down-regulation, the dose was
reduced to 0.4 mg/d, and recombinant FSH (rFSH; Gonal
F: Serono, Geneve, Switzerland; Puregon: Organon, Oss,
The Netherlands) was added until either the leading folli-
cle reached a mean diameter of 18 mm or two or more fol-
licles reached a diameter of 17 mm. For the GnRH
antagonist multiple-dose flexible protocol (n = 155),
rFSH was started on the 2nd or 3rd menstrual-cycle day
(with or without previous oral contraceptive pretreat-
ment). The GnRH antagonist cetrolelix (Cetrotide:
Serono) or ganirelix (Orgalutran: Organon), 0.25 mg/d,
sc, was added daily, starting when the leading follicle
reached a diameter of 12 mm and until either the leading
follicle reached a mean diameter of 18 mm or two or more
follicles reached a diameter of 17 mm. For both protocols,
the initial rFSH dose was chosen according to the female
characteristics, with no significant differences being
observed between patients allocated to the agonist or the
antagonists groups. Starting doses of rFSH ranged
between 100–185 IU, 200–250 IU and 300–450 IU. Inde-
pendently of the protocol to which patients were submit-
ted, higher rFSH starting doses were associated with
increased female age, basal FSH, body mass index and
number of previous attempts, and with decreased ovarian
volume and total number of antral follicles. For both pro-Reproductive Biology and Endocrinology 2009, 7:5 http://www.rbej.com/content/7/1/5
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tocols, urinary hCG (5,000–10,000 IU, im; Pregnyl: Orga-
non) was administered 35 h before recovery of large
ovarian follicles by ultrasonically-guided follicular aspira-
tion, using flush medium (Medicult, Copenhagen, Den-
mark). Embryo transfer was performed under
ultrasonography. All patients had luteal supplementation
with three times daily intravaginal administration of 200
mg natural-micronized progesterone (Utrogestan, Jaba,
Berlin, Germany). Implantation was confirmed by a rise
in serum β-hCG on days 12 and 14 after embryo transfer.
A clinical pregnancy was established by ultrasonography
at 5–7 weeks of gestation. All couples agreed to have an
integrated biochemical screening (at 12 and 15 weeks)
and prenatal diagnosis in case of a positive test.
Laboratorial procedures
Ejaculates were submitted to gradient centrifugation
(Suprasperm System, Medicult), washed and incubated
(5% CO2, 37°C, in filtrated humidified atmosphere) in
sperm preparation medium (SPM; Medicult) to collect the
swim-up fraction. Oocytes were denuded enzymatically
(Synvitro Hyadase, Medicult) and mechanically
(SweMed, Frolunda, Sweden). After culture in IVF
medium (Medicult) for 2 h, they were microinjected as
described in SPM [34]. They were then cultured in ISM1
medium (Medicult) for 2 days and then changed to ISM2
(Medicult). Normal fertilization was assessed 14–18
hours after injection, and embryo quality was evaluated
according to the number, size and regularity of the blast-
omeres, and the percentage of fragments (high quality
embryos were those with the correct number of cells, with
similar size and regularity, and with less than 25% of frag-
ments). Embryos were frozen with Embryo Freezing
Medium (day 3) or with Blast Freeze (day 5) (Medicult) in
an automatic freezing apparatus (Planer, Kryo 10 Series
III).
Statistical analysis
For a characterization of the study population, a descrip-
tive analysis was done. Statistical analyses were performed
using chi-square test (with Yates's continuity correction),
Student's t-test and Mann-Whitney test as appropriate. In
order to investigate possible predictors of ovarian
response, the first stage of the analysis was to establish
which of the factors were significantly associated with
ovarian responsiveness. The end point was the number of
oocytes retrieved and of embryos with high morphologi-
cal quality. Statistical analysis was performed using uni-
variable linear regression analysis, with the number of
oocytes and embryos as dependent variables, to deter-
mine which variables predicted the outcomes. Multiple
regression analysis by least-squares regression was then
used to evaluate the predictive values of the different
parameters in a stepwise manner. All predictive variables
were entered the model as independent variables: age,
type of protocol, basal estradiol and FSH levels, number
of antral follicles, ovarian volume, body mass index
(BMI), smoking status, total number of attempts and
cause of infertility (male factor alone or male+female fac-
tors). All the variables were continuous except for the type
of protocol, cause of infertility and smoking status, which
were binary variables. Correlation was assessed by the
Pearson's correlation coefficients.
The second stage of the analysis was to identify significant
predictors of pregnancy. Comparisons were made
between pregnant and non-pregnant groups. In multivar-
iable analysis, the Multiple Logistic Regression was used
to determine the independent effect of individual varia-
bles on clinical pregnancy. First, variables which were sig-
nificant at P < 0.25 in the univariable analysis were
considered as candidates for the multiple logistic regres-
sion model, to minimize erroneous exclusion of factors of
prognostic relevance. Second, a stepwise approach was
applied. Finally, the regression model was calculated only
with the covariates that were found to have a significant
effect (P < 0.05) on any of the first two steps. Adjusted
odds ratio and 95% Confidence Intervals (CI) resulting
from the final model were estimated for all the factors
remaining in the model.
For both multiple logistic regression and multiple regres-
sion models, the stepwise procedure deletes subjects with
missing data for any variable which is considered in the
model, so that once the final set of variables associated
with the outcome was identified, the model was rerun
using only the significant variables. This method ensures
that the final model is based on the largest possible sam-
ple size. Both forward and backward selection methods
were used to obtain the smallest number of explanatory
variables that provided a well-fitting model. For both
multiple logistic regression and multiple regression mod-
els, the continuous variable modelling was tested by the
fractional polynomial method, a procedure that makes
use of the full information available in the data when a
linear relationship is not assumed [35]. This approach was
used for finding the best fitting functional form between
the response variable and one or more continuous covari-
ates, after considering a set of possible transformations
[36]. Specific interactions between parameters of interest
were also investigated. The area under the Receiver Oper-
ating Characteristic (ROC AUC) curve was computed to
assess the predictive accuracy of the logistic model, yield-
ing values from 0.5 (no predictive power) to 1.0 (perfect
prediction). The Hosmer-Lemeshow goodness of fit test
was used to check for lack of fit of the final logistic model.
All statistical tests were two-tailed and a P value lower
than 0.05 was considered to be statistically significant.
Statistical analyses of the data were performed with SPSS,
version 15.0 and STATA, version 9.0.Reproductive Biology and Endocrinology 2009, 7:5 http://www.rbej.com/content/7/1/5
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Results
A total of 278 ICSI cycles were included in the study after
controlled ovarian hyperstimulation using a GnRH ana-
logue, 123 with an agonist (44.2%) and 155 with antago-
nists (55.8%). Female age (range: 23–44 years) group
distribution was 26.3% (≤ 29 years), 39.2% (30–34
years), 24.8% (35–39 years) and 9.7% (≥ 40 years). Of the
women, 61 (21.9%) were smokers and 217 (78.1%) non-
smokers. Causes of infertility were identical between the
two stimulation protocol groups, with 65.5% being due
to male factor only, 4.7% female factor only, 28.1%
male+female factors and 1.8% idiopathic. Cumulatively,
93.5% were due to male factor, 14.7% ovulation disor-
ders, 7.2% endometriosis, 6.8% uterine factor, 5.0% tubar
factor and 2.2% other female factors. Embryo transfer was
carried out in 270 (97.1%) patients. Lack of transfer was
caused by insufficient ovarian response (n = 2), fertiliza-
tion failure (n = 3), risk of ovarian hyperstimulation syn-
drome (n = 2) and poor-quality embryos for transfer (n =
1). The pregnancy rates per 270 embryo transfers were
35.9% (97 biochemical), 31.1% (84 clinical) and 27.8%
(75 term). Thus, there was a 22/97 (22.7%) rate of
embryo loss, 13/97 (13.4%) from biochemical to clinical
pregnancy and 9/84 (10.7%) from clinical to term preg-
nancy. The latter was due to 1/84 (1.2%) ectopic preg-
nancy and 8/84 (9.5%) first trimester spontaneous
abortions. Of the clinical pregnancies, 72.6% were single-
tons and 25% twins, giving an implantation rate of
18.2%. Although no women were admitted to the hospi-
tal, 21 (7.6%) had mild/moderate ovarian hyperstimula-
tion syndrome (OHSS). Table 1 summarizes the
demographic data and ovarian responses. Patient baseline
characteristics were identical between the two treatment
groups with the exception of a significant lower duration
of GnRH analogue (4.3 ± 1.2 vs. 27.6 ± 7.0, P < 0.001) and
rFSH (8.9 ± 1.3 vs. 11.1 ± 3.0, P < 0.001) treatment in the
antagonist group. Laboratorial data showed in the antag-
onist group a significant higher number of retrieved
cumulus-oocyte complexes (11.1 ± 6.0 vs. 8.0 ± 4.5, P <
0.001), metaphase II oocytes (9.0 ± 5.1 vs. 6.7 ± 3.8, P <
0.001) and high quality embryos (5.3 ± 3.9 vs. 3.2 ± 2.5,
P < 0.001), and a higher embryo cleavage rate (98% vs.
96%, P = 0.027), whereas the agonist group exhibited a
significant higher fertilization rate (79.2% vs. 71.3%, P <
0.001) and a relative higher number of transferred
embryos (2.4 ± 0.7 vs. 2.1 ± 0.6, P = 0.001). No significant
differences between groups were found regarding clinical
outcome variables, with 16.1% vs. 20.6% of implantation
rate, 34.8% vs. 36.5% of biochemical, 27.8% vs. 35.3% of
clinical, and 26.5% vs. 29.4% of term pregnancy rate per
Table 1: Summary of demographic data and ovarian responses.
Parameters
Number of cycles 278
Female age (years) 32.8 ± 4.7
Duration of infertility (years) 4.7 ± 3.4
Type of infertility
Primary (never pregnant) 237 (85.3)
Secondary 41 (14.7)
Number of attempts 1.6 ± 1.0
Basal FSH (mIU/ml) 6.4 ± 2.4
Basal E2 (pg/ml) 60.3 ± 58.7
BMI (Kg/m2) 23.0 ± 3.5
Ovarian volume (cm3)
Right 6.4 ± 4.3
Left 6.0 ± 3.8
Total 12.3 ± 6.4
Total number of antral follicles
Right 3.1 ± 2.1
Left 3.0 ± 2.0
Total 6.0 ± 3.8
Total rFSH administered (IU) 2139.2 ± 930.6
Duration of rFSH administration (days) 9.9 ± 2.5
Number of follicles > 17 mm 4.4 ± 2.1
Number of oocytes 9.7 ± 5.6
Number of metaphase II oocytes 8.0 ± 4.7
Number of fertilized oocytes 5.9 ± 3.7
Number of cleaved embryos 5.8 ± 3.6
Number of transferred embryos 2.2 ± 0.7
Endometrial thickness (mm) 10.3 ± 1.6
Serum E2 on hCG administration day (pg/ml) 1944.4 ± 1135.1
Data in N, N (%) or mean ± SD.Reproductive Biology and Endocrinology 2009, 7:5 http://www.rbej.com/content/7/1/5
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transfer, respectively for women subjected to an antago-
nist or agonist protocol.
Predictors of the number of retrieved oocytes
Ten predictor variables were considered with the depend-
ent variable being the number of retrieved oocytes (age,
type of protocol, basal estradiol and FSH levels, total
number of antral follicles, ovarian volume, BMI, smoking
status, number of attempts, cause of infertility, male or
male+female). Only five factors were found significant in
the univariable analysis: female age and basal FSH were
variables inversely related to the number of retrieved
oocytes, whereas the total ovarian volume and total
number of antral follicles had a positive correlation to the
ovarian response. The patients from the antagonist proto-
col had a larger number of oocytes retrieved than patients
treated with the agonist protocol (Table 2).
After adjusting for the effects of a large set of variables,
multiple regression analysis showed that the total number
of retrieved oocytes could be predicted by the female age,
type of protocol, basal FSH and total number of antral fol-
licles, with all other parameters being excluded from the
equation. Although the ovarian volume was a significant
predictor of the number of retrieved oocytes in the univar-
iable analysis, it was not an independent predictor in the
multiple regression model. This could occur because the
ovarian volume was significantly correlated with the
dependent variables basal FSH serum levels (R = -0.130, P
= 0.030) and total number of antral follicles (R = 0.219, P
< 0.001). The results obtained with this stepwise proce-
dure were also compared with both backward and for-
ward selection methods to identify the smallest number
of explanatory variables that provided a well-fitting
model. The possible interactions were examined but none
of these were significant. We also checked the correct form
for continuous variables in the model, using the fractional
polynomial method. None of the alternative models was
however significantly better than the one considering the
linearity of variables. From the multivariable model, the
calculated formula to estimate the number of retrieved
oocytes was:
Total (COC) = 13.270 + 2.667(GnRH) - 0.854(FA/5) -
0.343(FSH) +0.459(TAF)
with
GnRH (agonist = 0; antagonist = 1), FA (female age), FSH
(basal FSH), and TAF (Total Antral Follicles).
Predictors of the number of high quality embryos attained
Once only cycles with transfer of high quality (grade A/B)
embryos resulted in pregnancy (21 cycles without preg-
nancy after transfer of only low quality embryos), we
identified those factors that affected the number of high
quality embryos attained. Data was log-transformed to
achieve the residual normality required in linear regres-
sion [ln (number of high quality embryos + 1)], as the
number of high quality embryos could take the zero
value. First, a univariable analysis was made using the
same group of variables studied for the total number of
oocytes retrieved, as well as sperm concentration, rapid
progressive motility and normal morphology. This
Table 2: Significant predictors of the number of retrieved oocytes and high quality embryos by linear regression.
Univariable analysis Multivariable analysis
Parameters R2 Unstandardized 
coefficients
P value Unstandardized 
coefficients
Standardized 
coefficients
P value
Number of retrieved 
oocytes
Protocol (a) 0.072 3.030 < .001 2.667 0.237 < .001
Female age (b) 0.067 - 1.556 < .001 - 0.854 - 0.142 .010
Basal FSH (mIU/ml) 0.079 - 0.656 < .001 - 0.343 - 0.147 .009
Total ovarian volume (cm3) 0.026 0.141 .007
Total number of antral 
follicles
0.141 0.554 < .001 0.459 0.311 < .001
Number of high quality 
embryos (c)
Protocol (a) 0.074 0.379 < .001 0.345 0.247 < .001
Female age (b) 0.071 - 0.199 < .001 - 0.136 - 0.182 .002
Basal FSH (mIU/ml) 0.068 - 0.076 < .001 - 0.048 - 0.165 .005
Total ovarian volume (cm3) 0.015 0.013 .045
Total number of antral 
follicles
0.041 0.037 .001 0.024 0.132 .022
(a) Agonist protocol as reference. (b) For a 5 year increase. (c) Data was log transformed: ln (number of high quality embryos + 1).
Negative coefficients for inversely related variables. Number of retrieved oocytes: model accounts for 25% variability of the number of retrieved 
oocytes. Number of high quality embryos: model accounts for 17% variability of the number of high quality embryos.Reproductive Biology and Endocrinology 2009, 7:5 http://www.rbej.com/content/7/1/5
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revealed the same significant predictors as above. Female
age and basal FSH were inversely related to the number of
high quality embryos, whereas the total ovarian volume
and the total number of antral follicles had a positive cor-
relation. Patients from the antagonist group tended to
have a larger number of high quality embryos than
patients treated with the agonist protocol (Table 2). Using
the multiple regression model, we determined the set of
factors that independently predicted the number of high
quality embryos. Female age and basal FSH remained sig-
nificant risk factors for reduced high quality embryo num-
bers, and elevations in the total number of antral follicles
tended to increase the number of high quality embryos.
Belonging to the antagonist protocol group was associated
with a higher number of high quality embryos. From the
multivariable model, the calculated formula to estimate
the number of high quality embryos was:
ln(total AB embryos + 1) = 2.316 + 0.345(GnRH) - 
0.136(FA/5)- 0.048(FSH) + 0.024(TAF)
with
GnRH (agonist = 0; antagonist = 1), FA (female age), FSH
(basal FSH), and TAF (Total Antral Follicles).
Predictors of pregnancy
The analysis was extended to identify significant predic-
tors of pregnancy. Comparisons of baseline characteristics
and ovarian response data between pregnant and non-
pregnant groups showed that in the pregnant group the
patients were significantly younger, had a lower duration
of infertility, fewer number of attempts, lower basal FSH
levels, lower total dose of rFSH administered, higher num-
bers of mature and fertilized oocytes, higher numbers of
embryos and higher endometrial thickness (Table 3). The
multiple logistic regression model with the dependent
Table 3: Comparison of baseline data and cycle characteristics in ICSI cycles between pregnant and non-pregnant patients (clinical 
pregnancy).
Parameters Pregnant Non-Pregnant P value
Number of cycles 84 186
Female age (years) 31.4 ± 3.8 33.3 ± 4.8 .006
Duration of infertility (years) 3.9 ± 2.7 4.9 ± 3.5 .018
Type of infertility .202
Primary (never pregnant) 75 (89.3) 154 (82.8)
Secondary 9 (10.7) 32 (17.2)
Type of protocol .233
Antagonist 42 (50.0) 109 (58.6)
Agonist 42 (50.0) 77 (41.4)
Number of attempts 1.3 ± 0.8 1.6 ± 1.1 .001
Basal FSH (mIU/ml) 5.8 ± 1.9 6.6 ± 2.5 .025
Basal E2 (pg/ml) 54.8 ± 48.6 61.6 ± 63.0 .367
BMI (Kg/m2) 23.1 ± 3.7 22.9 ± 3.4 .846
Total ovarian volume (cm3) 13.4 ± 7.8 11.9 ± 5.7 .252
Total number of antral follicles 6.4 ± 4.1 6.0 ± 3.7 .694
Initial FSH dose (IU) 190.8 ± 53.3 212.2 ± 66.6 .009
Total rFSH administered (IU) 1961.3 ± 884.3 2210.7 ± 928.7 .012
Duration of rFSH administration (days) 9.8 ± 2.2 10.0 ± 2.6 .503
Number of follicles ≥ 17 mm 4.4 ± 2.1 4.3 ± 2.0 .765
Number of retrieved oocytes 10.2 ± 4.6 9.6 ± 5.8 .070
Number of metaphase II oocytes 8.7 ± 4.2 7.8 ± 4.7 .031
Number of fertilized oocytes 6.7 ± 3.5 5.7 ± 3.6 .013
Number of cleaved embryos 6.5 ± 3.4 5.5 ± 3.6 .008
Number of transferred embryos 2.2 ± 0.7 2.2 ± 0.7 .958
Embryo transfer day 1.000
Day 3 56 (66.7) 124 (66.7)
Day 5 28 (33.3) 62 (33.3)
Number of high quality embryos transferred .802
1 12 (14.3) 29 (17.6)
2 50 (59.5) 94 (57.0)
3 22 (57.8) 42 (25.5)
Endometrial thickness (mm) 10.6 ± 1.6 10.2 ± 1.5 .038
Serum E2 on hCG administration day (pg/ml) 1885.3 ± 1009.8 1963.0 ± 1168.4 .803
Data in N, N (%) or mean ± standard deviation.Reproductive Biology and Endocrinology 2009, 7:5 http://www.rbej.com/content/7/1/5
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variable being the occurrence of clinical pregnancy was
restricted to cycles with transfer of high quality embryos
and therefore the model is only valid for those cases.
Women without transfer of high quality embryos had no
pregnancy and this could lead to a numerical problem in
statistics. The agonist protocol, less number of attempts,
each additional millimetre of endometrial thickness and
female age were independently and significantly associ-
ated with achievement of clinical pregnancy (Table 4).
The possible interactions were examined but none of
these were significant.
Fractional polynomial modelling confirmed that the asso-
ciation with age was not linear. The variable age was thus
represented in the model by two terms, (Age/10)3 and
(Age/10)3 × ln (Age/10), to properly represent its func-
tional relationship with the probability of getting preg-
nant as determined by preliminary goodness-of-fit
analyses. The interpretation of the variable age is not so
simple once it was not included in the model in the linear
form, but was modelled by the method of fractional pol-
ynomials. To achieve a better understanding, we calcu-
lated the estimated adjusted odds ratios for the
probability of achieving a clinical pregnancy for female
patients of different ages relatively to a 25 years-old
patient, considered as the reference, while the other varia-
bles in the model were held constant (Table 5). Women
30 years-old were 1.5 times more likely to become preg-
nant than those with 25 years, 35 years-old women had a
similar probability as the reference age, and 40 years-old
women had about 4 times less. It seems to be an early
increase of the probability to achieve pregnancy until 30
years-old, with a decline after that age and with a sharp
decline in women whose ovaries have more than 40 years.
To assess the fit of the final logistic model, the Hosmer-
Lemeshow test was calculated and demonstrated no lack
of fit (P = 0.155). The diagnostic accuracy of the model to
discriminate between pregnant and non-pregnant cases
was analysed using the ROC curve and AUCROC value (Fig.
1). Its discriminative power was modest (0.707; values
vary from 0.5, no predictive power, to 1.0, perfect predic-
tion).
Accordingly (Table 4) the calculated formula to estimate
the probability of pregnancy for the given values of the
predictive variables in the model was:
Probability of Clinical Pregnancy = eη/(1 + eη)
where
η = -0.085 - 0.454(NA - 1.528) + 0.190(ET - 10.32) + 
0.517 [(FA/10)3 - 34.47] - 0.355 [(FA/10)3 × ln(FA/10) - 
40.67] - 0.579(GnRH)
with
NA (number of attempts), ET (endometrial thickness), FA
(female age), GnRH (agonist = 0; antagonist = 1).
The estimated probability of clinical pregnancy for hypo-
thetical cases was calculated considering the type of proto-
col, number of previous attempts, female age and
endometrial thickness (Table 6).
Discussion
Studies comparing the efficacy of the ovarian stimulation
with GnRH analogues using univariable analysis [3-7,9]
or meta-analysis of randomized controlled trials [14],
showed no significant differences in pregnancy rates
between antagonist and agonists. In contrast, other meta-
analyses of randomized controlled studies [12,13] and
reviews based on randomized studies [37,38], have
shown that if the antagonist protocol avoids the adverse
effects of agonists and is significantly associated with a
lower duration of treatment and total administered doses
of the GnRH analogue and of rFSH, the agonist regimen
appears associated with higher numbers of oocytes and
embryos and with higher implantation and pregnancy
rates. However, with the exception of a single study, which
showed that the chance of pregnancy was significantly
improved when a GnRH agonist ultrashort protocol was
used in detriment of clomiphene citrate [27], the stimula-
tion protocol has not been included in the multivariable
analysis of those studies.
Table 4: Significant predictors of clinical pregnancy by multiple logistic regression.
Adjusted OR (b) CI 95% P value
Type of protocol
Agonist (a) 1 .045
Antagonist 0.561 0.318 – 0.988
Number of attempts 0.635 0.430 – 0.936 .022
Endometrial thickness (mm) 1.209 1.010 – 1.447 .039
(Female age/10)3 1.677 1.058 – 2.657 .028
(Female age/10)3 × ln (Female age/10) 0.701 0.518 – 0.948 .021
(a) Reference category. (b) Odds Ratios < 1 are associated with decreased probability of pregnancy.Reproductive Biology and Endocrinology 2009, 7:5 http://www.rbej.com/content/7/1/5
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The present study was primarily designed to investigate
the predictive value of the stimulation protocol and to
analyze the possible relationships between stimulation
protocols and treatment outcomes after adjusting for a
large set of variables that potentially affect reproductive
outcomes. Nevertheless, the present study design has as
main limitation the fact of being an observational pro-
spective study and not a randomized controlled trial.
However, as the two studied groups were comparable, the
possibility of selection appears minimal. We here show
that the ovarian stimulation protocol affects the reproduc-
tive outcomes, with patients in the antagonist group hav-
ing lower duration of rFSH administration, higher
numbers of retrieved oocytes and high quality embryos,
whereas those from the agonist group will present higher
fertilization rates.
Regarding predictors of the number of retrieved oocytes
and high quality embryos, the present multiple regression
analysis showed a positive association with use of the
antagonist protocol and the total number of antral folli-
cles, and a negative association with increasing maternal
age and basal serum levels of FSH. For the ovarian
response, these results are in agreement with others rela-
tively to female age, serum basal FSH and the total
number of antral follicles [19-23,26,28,30,39]. The model
explained only 25% of the variation of the ovarian
response, which is in accordance (25–38%) to other stud-
ies [20,22,23,28], and 17% of the variability of the
number of high quality embryos. These values strongly
suggest that variability may be due to inherent biological
mechanisms as also to parameters that may not be consid-
ered or only partially controlled, particularly genetic fac-
tors [40].
The present study also demonstrated that the likelihood
of pregnancy is positively associated with use of the ago-
nist stimulation protocol, less number of attempts and
higher endometrial thickness. The likelihood of getting
pregnant was also shown to increase up to age 30, decreas-
ing afterwards, with a sharp decline for women above 40
years-old. Regarding female age, number of attempts and
endometrial thickness, our present results are in agree-
ment with previous studies [16,21,24-
27,29,30,33,41,42]. However, in contrast with other stud-
ies, higher serum basal levels of FSH and estradiol, longer
duration of infertility, female smoking, combined male
and female factor infertility or multiple female infertile
factors were not found as significant negative predictors of
pregnancy [16,19,21,25,26,30,31,42]. Similarly, the
present data also do not support idiopathic infertility,
ovulation dysfunction other than diminished ovarian
reserve, higher serum levels of estradiol on the day of hCG
injection, and higher numbers of oocytes, embryos, high
quality embryos and transferred embryos as significant
positive predictors of pregnancy achievement
[21,24,25,27,29,30].
Although the pregnancy rates did not differ between both
protocols, the multiple logistic regression analysis con-
firmed a marginal but significant higher probability of
ROC curve for multiple logistic regression model Figure 1
ROC curve for multiple logistic regression model. 
The diagonal line is the line of no discrimination.
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Table 5: Estimated odds ratio by female age regarding the 
occurrence of a clinical pregnancy.
Female age (years) OR CI 95%
25 (a) 1
26 1.138 0.973 – 1.331
27 1.272 0.940 – 1.719
28 1.391 0.901 – 2.147
29 1.485 0.855 – 2.579
30 1.542 0.802 – 2.967
31 1.554 0.743 – 3.252
32 1.514 0.678 – 3.384
33 1.422 0.607 – 3.330
34 1.283 0.533 – 3.092
35 1.108 0.454 – 2.708
36 0.914 0.372 – 2.242
37 0.716 0.290 – 1.767
38 0.532 0.210 – 1.344
39 0.373 0.138 – 1.003
40 0.246 0.081 – 0.747
41 0.152 0.041 – 0.562
42 0.087 0.018 – 0.427
43 0.047 0.007 – 0.326
44 0.023 0.002 – 0.249
(a) Reference category.Reproductive Biology and Endocrinology 2009, 7:5 http://www.rbej.com/content/7/1/5
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achieving a clinical pregnancy in the agonist group (OR =
0.561; 0.318–0.988; P = 0.045). Because the antagonist
group had a higher loss of early implanted embryos (bio-
chemical to clinical pregnancy, 22.2% vs. 2.3%) and a
lower loss of well implanted embryos (clinical to term
pregnancy, 4.8% vs. 16.7%), the lower probability of a
successful clinical pregnancy after antagonist treatment
might be associated with endometrial characteristics or
the genetical profile of the oocytes and embryos [10,43].
In conclusion, the present study analyzed the impact of
the stimulation protocol on reproductive outcomes
adjusting for an extended number of potential risk factors,
providing useful information about the independent pre-
dictors of ovarian response, production of high quality
embryos and occurrence of a clinical pregnancy. Quanti-
tative data showed that the antagonist protocol is associ-
ated with more oocytes and high quality embryos than the
agonist. Although it seemed to be a trend towards higher
pregnancy rates in the agonist group, this association was
marginal (P = 0.045), not allowing an evident distinction
of benefits between each protocol on achieving a preg-
nancy. Data also showed that not only the protocol
affected the outcomes but also factors as female age,
serum basal levels of FSH, total number of antral follicles,
number of previous treatment attempts, and
endometrium thickness should be analysed when the pur-
pose is to choose a therapy and assess the chance of suc-
cess for better counselling patients before undergoing an
ICSI treatment.
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